Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
|Articles|June 1, 2005
What Happens in the Brain? S2Treating Alcohol Abuse and Dependence S5CME Post-Test S10CME Registration/Evaluation Form S11
Vice Chair, Department of Psychiatry Director of Addiction Medicine Cedars-Sinai Medical Center Adjunct Professor of Psychiatry University of California, Los Angeles
Advertisement
Contents
Faculty
Vice Chair, Department of Psychiatry Director of Addiction Medicine Cedars-Sinai Medical Center Adjunct Professor of Psychiatry University of California, Los Angeles
Professor of Psychiatry University of California, San Diego Director, Alcohol Research Center San Diego Veterans Affairs Medical Center San Diego
Professor of Neuropharmacology Director, Division of Clinical Psychopharmacology Codirector, Pearson Center for Alcoholism and Addiction Research Scripps Research Institute La Jolla, Calif
Advertisement
Related to this article
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
Advertisement
Advertisement
Trending on Patient Care Online
1
Stroke Incidence Nearly Doubled Among Adults Younger Than 55 Over 3 Decades
2
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
3
ACCORD Trials: Efficacy and Safety of Dextromethorphan-Bupropion in Agitation
4
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
5